Luminex’ multiplexing platform will be utilized to create diagnostics for solid tumors.

Luminex and BD are joining forces to develop molecular diagnostics for certain cancers. BD Diagnostics-TriPath will develop, market, and sell these tests using Luminex’ multiplexing xMAP® Technology platform.

BD develops technologies for cervical cancer screening as well as diagnostic products for the detection of cancer. The aim is to expand its offerings to include tests for solid tumor cancers using Luminex’ platform.

The xMAP Technology is a multiplexing platform that allows scientists to conduct multiple, simultaneous tests on one patient sample. “We believe providing biomarker testing in a multiplex format would allow detection of cancer at an earlier stage,” says Wayne Brinster, vp and GM of BD Diagnostics-TriPath.

This site uses Akismet to reduce spam. Learn how your comment data is processed.